Theravance Biopharma, Inc. (TBPH)
17.02
+0.02
(+0.09%)
USD |
NASDAQ |
Aug 25, 15:53
Theravance Biopharma Debt to Equity Ratio : 0.2463 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2463 |
| March 31, 2026 | 0.2522 |
| December 31, 2025 | 0.2544 |
| September 30, 2025 | 0.1917 |
| June 30, 2025 | 0.2066 |
| March 31, 2025 | 0.4768 |
| December 31, 2024 | 0.2838 |
| September 30, 2024 | 0.2423 |
| June 30, 2024 | 0.2409 |
| March 31, 2024 | 0.2338 |
| December 31, 2023 | 0.2308 |
| September 30, 2023 | 0.2065 |
| June 30, 2023 | 0.1845 |
| March 31, 2023 | 0.1382 |
| December 31, 2022 | 0.1181 |
| September 30, 2022 | 0.1084 |
| June 30, 2022 | -1.938 |
| March 31, 2022 | -1.915 |
| December 31, 2021 | -1.978 |
| September 30, 2021 | -2.074 |
| June 30, 2021 | -2.225 |
| March 31, 2021 | -1.801 |
| December 31, 2020 | -2.226 |
| September 30, 2020 | -2.557 |
| June 30, 2020 | -3.252 |
| Date | Value |
|---|---|
| March 31, 2020 | -4.148 |
| December 31, 2019 | -2.281 |
| September 30, 2019 | -2.800 |
| June 30, 2019 | -3.730 |
| March 31, 2019 | -4.518 |
| December 31, 2018 | -8.807 |
| September 30, 2018 | -16.70 |
| June 30, 2018 | 6.522 |
| March 31, 2018 | 3.533 |
| December 31, 2017 | 1.943 |
| September 30, 2017 | 1.214 |
| June 30, 2017 | 0.9257 |
| March 31, 2017 | 0.7584 |
| December 31, 2016 | 0.6358 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Zymeworks, Inc. | 3.343 |
| Viatris, Inc. | 0.9555 |
| Ocular Therapeutix, Inc. | 0.1526 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 469.77M |
| Total Liabilities (Quarterly) | 180.06M |
| Shareholders Equity (Quarterly) | 289.70M |
| Current Ratio | 13.54 |
| Net Debt Paydown Yield | 0.18% |